Development Status and Prospect of Therapeutic Radiopharmaceuticals

Therapeutic radiopharmaceuticals combine radionuclides with carriers. It uses radionuclide suitable radiation energy and range in the tissue, selectively concentrated irradiation of diseased tissue, while avoiding damage to normal tissue and achieving the desired therapeutic effect. It is mainly used for cancer treatment or relief of tumor-related symptoms. It is widely used in tumor diagnosis and treatment, myocardial imaging, early detection of neurodegenerative diseases and imaging diagnosis of inflammatory tissues. In recent years, with the rapid development of targeted ligands and the wide application of new medical nuclides, radiotherapeutic drugs have attracted more and more attention. At present, nuclides such as 153Sm, 89Sr, 223Ra, 90Y, 131I and 177Lu are commonly used to treat cancer, bone metastasis, liver cancer and thyroid cancer, and show exciting potential in treatment. The research on radiotherapeutic drugs is also increasing rapidly. The clinical application and development status of radiopharma in the market and in the research stage are briefly introduced, in order to provide reference for the research and development of radiopharma in China.